Biopharma recognizes that a new paradigm of clinical trial monitoring is critical to success. Risk-based Monitoring (RBM) is an accepted method covered by FDA draft guidance and an EMA reflection paper. This approach involves adjusting the monitoring strategy based on level of risk, reflecting the reality that 20% of clinical trial sites contribute to 80% of quality issues.

To hear more about Risk-based Monitoring, click each segment below.